Bispecific antibodies amivantamab and tarlatamab hold promise for patients.
December 2024
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia.
The program develops patient-centered oncology pharmacists through comprehensive training.
Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.
Peer Reviewed
This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.
Pharmacists bring a unique perspective to health care that bridges clinical knowledge, patient-centered care, and operational expertise.
The treatment landscape for multiple myeloma continues to evolve.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Sotatercept-csrk for Pulmonary Arterial Hypertension
2
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
3
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
4
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
5
